The majority of lung cancer patients progressing from conventional therapies are refractory to
PD
‐L1/
PD
‐1 blockade monotherapy. Here, we show that baseline systemic
CD
4 immunity is a differential factor for clinical responses. Patients with functional systemic
CD
4 T cells included all objective responders and could be identified before the start of therapy by having a high proportion of memory
CD
4 T cells. In these patients,
CD
4 T cells possessed significant proliferative capacities, low co‐expression of
PD
‐1/
LAG
‐3 and were responsive to
PD
‐1 blockade
ex vivo
and
in vivo
. In contrast, patients with dysfunctional systemic
CD
4 immunity did not respond even though they had lung cancer‐specific T cells. Although proficient in cytokine production,
CD
4 T cells in these patients proliferated very poorly, strongly co‐upregulated
PD
‐1/
LAG
‐3, and were largely refractory to
PD
‐1 monoblockade.
CD
8 immunity only recovered in patients with functional
CD
4 immunity. T‐cell proliferative dysfunctionality could be reverted by
PD
‐1/
LAG
‐3 co‐blockade. Patients with functional
CD
4 immunity and
PD
‐L1 tumor positivity exhibited response rates of 70%, highlighting the contribution of
CD
4 immunity for efficacious
PD
‐L1/
PD
‐1 blockade therapy.
Hyperprogressive disease (HPD) is an adverse outcome of immunotherapy consisting of an acceleration of tumor growth associated with prompt clinical deterioration. The definitions based on radiological evaluation present important technical limitations. No biomarkers have been identified yet. In this study, 70 metastatic NSCLC patients treated with anti-PD-1/PD-L1 immunotherapy after progression to platinum-based therapy were prospectively studied. Samples from peripheral blood were obtained before the first (baseline) and second cycles of treatment. Peripheral blood mononuclear cells (PBMCs) were isolated and differentiation stages of CD4 lymphocytes quantified by flow cytometry and correlated with HPD as identified with radiological criteria. A strong expansion of highly differentiated CD28− CD4 T lymphocytes (CD4 THD) between the first and second cycle of therapy was observed in HPD patients. After normalizing, the proportion of posttreatment/pretreatment CD4 THD was significantly higher in HPD when compared with the rest of patients (median 1.525 vs. 0.990; p = 0.0007), and also when stratifying by HPD, non-HPD progressors, and responders (1.525, 1.000 and 0.9700 respectively; p = 0.0025). A cut-off value of 1.3 identified HPD with 82% specificity and 70% sensitivity. An increase of CD28− CD4 T lymphocytes ≥ 1.3 (CD4 THD burst) was significantly associated with HPD (p = 0.008). The tumor growth ratio (TGR) was significantly higher in patients with expansion of CD4 THD burst compared to the rest of patients (median 2.67 vs. 0.86, p = 0.0049), and also when considering only progressors (median 2.67 vs. 1.03, p = 0.0126). A strong expansion of CD28− CD4 lymphocytes in peripheral blood within the first cycle of therapy is an early differential feature of HPD in NSCLC treated with immune-checkpoint inhibitors. The monitoring of T cell dynamics allows the early detection of this adverse outcome in clinical practice and complements radiological evaluation.
The EORTC QLQ-CR29 is a reliable and valid instrument when applied to a sample of Spanish rectal cancer patients. These results are in line with those of the EORTC validation study.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.